Jana Jeschke

发表

Frequent Inactivation of Cysteine Dioxygenase Type 1 Contributes to Survival of Breast Cancer Cells and Resistance to Anthracyclines

Ludmila V. Danilova, J. Herman, K. Schuebel, 2013, Clinical Cancer Research.

Genome-wide hydroxymethylcytosine pattern changes in response to oxidative stress

F. Mascart, Jana Jeschke, A. Murrell, 2015, Scientific Reports.

MEXPRESS: visualizing expression, DNA methylation and clinical TCGA data

Jana Jeschke, W. Van Criekinge, A. Koch, 2015, BMC Genomics.

Genomic and Epigenomic Integration Identifies a Prognostic Signature in Colon Cancer

J. Herman, K. Schuebel, S. Baylin, 2011, Clinical Cancer Research.

KRAS G>A mutation favors poor tumor differentiation but may not be associated with prognosis in patients with curatively resected duodenal adenocarcinoma

N. Ahuja, C. Iacobuzio-Donahue, Jana Jeschke, 2013, International journal of cancer.

Why novel mRNA modifications are so challenging and what we can do about it

Jana Jeschke, F. Fuks, Audrey Penning, 2022, Nature Reviews Molecular Cell Biology.

The RNA demethylase FTO controls m6A marking on SARS-CoV-2 and classifies COVID-19 severity in patients

D. Lambrechts, L. Naesens, Jana Jeschke, 2022, bioRxiv.

Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells

S. Baylin, N. Ahuja, Jana Jeschke, 2017, PloS one.

Improving Infinium MethylationEPIC data processing: re-annotation of enhancers and long noncoding RNA genes and benchmarking of normalization methods

Gianluca Bontempi, C. Sotiriou, Jana Jeschke, 2022, Epigenetics.

Improving In�nium MethylationEPIC data processing: focus on enhancers and long noncoding RNA genes

Jana Jeschke, J. Jeschke, Christos Sotiriou, 2022 .

MEXPRESS update 2019

Jana Jeschke, W. Criekinge, T. Meyer, 2019, Nucleic Acids Res..

DNA methylation–based immune response signature improves patient diagnosis in multiple cancers

Gianluca Bontempi, Matthieu Defrance, Christine Desmedt, 2017, The Journal of clinical investigation.

DNA methylome profiling beyond promoters – taking an epigenetic snapshot of the breast tumor microenvironment

Jana Jeschke, F. Fuks, E. Collignon, 2015, The FEBS journal.

A Four-Gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients

P. A. van den Brandt, J. Herman, K. Schuebel, 2016, Clinical Cancer Research.

Sessile serrated adenomas and classical adenomas: An epigenetic perspective on premalignant neoplastic lesions of the gastrointestinal tract

J. Herman, L. V. Neste, S. Baylin, 2011, International journal of cancer.

Epigenetic silencing of neurofilament genes promotes an aggressive phenotype in breast cancer

J. Herman, K. Schuebel, S. Baylin, 2015, Epigenetics.

Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen

L. Cope, J. Herman, K. Schuebel, 2012, Epigenetics.

Portraits of TET-mediated DNA hydroxymethylation in cancer.

Jana Jeschke, F. Fuks, E. Collignon, 2016, Current opinion in genetics & development.

Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors

C. Sotiriou, C. Desmedt, K. Willard-Gallo, 2021, Nature Cancer.

CpG island methylator phenotype and its association with malignancy in sporadic duodenal adenomas

S. Baylin, N. Ahuja, C. Iacobuzio-Donahue, 2014, Epigenetics.